Vaccines expose the body to a very little number of weakened or dead viruses or bacteria, which is completely safe. If the body is later exposed to the virus, the immune system will detect it and attack it. The rising frequency of numerous infectious illnesses, as well as the increasing number of vaccine approvals by regulatory agencies, are likely to drive the worldwide vaccines market throughout the forecast period. Moreover, rising adoption of inorganic methods such as partnerships and collaborations by industry major players is likely to help in the expansion of the global vaccines market over the forecast period. Pfizer Inc., a pharmaceutical and biotechnology company, announced in June 2021 that the PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) received FDA approval for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults aged 18 years and older. The high cost of vaccine research and tight government requirements for product clearance are projected to be the primary factors impeding the growth of the global vaccines industry.
According to Coherent Market Insights, the global Vaccines Market is estimated to be valued at US$ 38,305.2 million in 2021 and is expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).
Key Companies in the vaccines Industry:
AstraZeneca GmbH
AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. In December, 2022 AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL)
GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GSK plc and Wave Life Sciences Ltd in December, 2022 announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.
Pfizer Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.
Sanofi S.A.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.